DOCMORRIS AG Well healthcare platform to go live shortly In recent months the joint venture set up by insurers CSS and Visana, Medi24 and the Zur Rose Group has laid the technological groundwork for running a comprehensive digital healthcare platform where Zur Rose provides part of the technology. The next step will be the market entry of the Well healthcare app. The platform will simplify access to personal healthcare services for users in Switzerland, creating a basis for digitally supported, integrated care.
Zur Rose Switzerland contributes to combating the pandemic As a systemically important provider of medicines, Zur Rose Switzerland has come up with innovative offerings in the struggle against the coronavirus. Jointly with Zur Rose subsidiary BlueCare, partner mediX and technical support from healthinal, it developed and financed a technological solution to simplify the processing of COVID-19 tests and vaccinations for doctors. The service is provided free of charge to all testing and vaccination facilities and is used by over 700 practices; more than 100,000 vaccinations and PCR tests have been administered.
Outlook In the second half of 2021 the main focus will be on the launch of e-prescriptions in Germany. The Zur Rose Group is keen to convince with its service and e-commerce offering and boost revenue in this area considerably in the future. With 10.3 million customers in the German market and DocMorris as Germany's best-known pharmacy brand, the Group is excellently placed to seize this opportunity. It is now laying the groundwork with a clear focus on winning new customers, raising brand awareness and brand positioning.
In a changing market environment where the trend towards digitalisation has accelerated sharply as a result of the pandemic, the Zur Rose Group is step-by-step changing from being a pure e-commerce pharmacy to a comprehensive healthcare service and healthtech provider. The focus is on creating and expanding the European healthcare ecosystem, where all the activities surrounding digital healthcare are brought together. This will make it possible for people to manage their health in one click. Zur Rose will drive ahead the European expansion. An accelerated trend towards digitalising the healthcare system is apparent in several countries. Zur Rose will seize the market opportunities that arise and roll out further growth initiatives.
The Zur Rose Group confirms the short and medium-term growth and earnings targets announced on 18 March 2021.
Revenue, in CHF million (unaudited) 1.4.-30.6.2021 1.4.-30.6.2020 Change Zur Rose Group external revenue 495.3 383.4 29.2% Zur Rose Group external revenue, in local currency 26.2% Zur Rose Group 418.8 333.0 25.8% Zur Rose Group, in local currency 23.1% Markets Germany external revenue 318.8 227.1 40.4% Germany external revenue, in local currency 35.6% Germany 242.4 176.8 37.1% Germany, in local currency 32.4% Switzerland 158.1 137.5 14.9% Europe 20.6 19.7 4.6% Europe, in local currency 1.2% Business models B2C external revenue 359.4 257.9 39.3% B2C 283.0 207.6 36.3% Professional Services 117.4 106.7 10.1% Marketplace 20.6 19.7 4.6% Revenue, in CHF million (unaudited) 1.1.-30.6.2021 1.1.-30.6.2020 Change Zur Rose Group external revenue 998.0 809.9 23.2% Zur Rose Group external revenue, in local currency 20.8% Zur Rose Group 839.8 698.0 20.3% Zur Rose Group, in local currency 18.2% Markets Germany external revenue 656.0 490.7 33.7% Germany external revenue, in local currency 30.0% Germany 497.8 378.8 31.4% Germany, in local currency 27.8% Switzerland 305.1 288.8 5.6% Europe 40.5 32.1 26.4% Europe, in local currency 22.9% Business models B2C external revenue 730.1 554.2 31.7% B2C 571.9 442.3 29.3% Professional Services 231.0 225.3 2.6% Marketplace 40.5 32.1 26.4%
External revenue consists of the consolidated revenue of the Zur Rose Group plus the mail-order revenue of pharmacies supplied by the Zur Rose Group, less the consolidated revenue for their supply.
Further key financials, in CHF million (unaudited) 1.1.-30.6.2021 1.1.-30.6.2020 Change
Earnings before interest, taxes, depreciation and amortization (EBITDA) adjusted -42.9 -11.5 n.m.
in % of revenue -5.1% -1.6%
Earnings before interest, taxes, depreciation and amortization (EBITDA) -49.7 -24.5 n.m.
in % of revenue -5.9% -3.5%
Earnings before interest and taxes (EBIT) -73.1 -42.0 n.m.
in % of revenue -8.7% -6.0%
Net income / (loss) -77.0 -52.3 n.m.
in % of revenue -9.2% -7.5%
30.6.2021 31.12.2020 Change
Equity 466.1 531.7 12.3%
in % of total assets 37.2% 41.6% The half-year report 2021 and presentation are available at www.zurrosegroup.com under "Investors & Media", "Publications".
At 2 p.m. CET today there will be a telephone conference in English for analysts and the media. CH: +41 44 580 65 22 | DE: +49 69 201 744 220 | UK: +44 203 009 24 70 | USA: +1 877 423 08 30 Conference ID: 85572921# The associated presentation (without audio) is available at: https://www.webcast-eqs.com/zurroseag20210818/no-audio Alternatively, the presentation can be followed via live audio webcast using the following link: Please dial in approx. 5 minutes before the conference call begins. https://www.webcast-eqs.com/zurroseag20210818 Investors and analyst contact Christoph Herrmann, Head of Investor Relations Email: ir@zurrose.com, phone: +41 58 810 11 49
Media contact Lisa Lüthi, Head of Group Communications Email: media@zurrose.com, phone: +41 52 724 08 14
Agenda 21 October 2021 Q3 Trading Update 20 January 2022 Sales 2021 24 March 2022 2021 Full-Year Results 20 April 2022 First Quarter Trading Update 28 April 2022 Annual General Meeting
Zur Rose Group The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand, DocMorris, and employs more than 2,200 people at sites in Switzerland, Germany, the Netherlands, Spain and France. Now serving more than 11 million active customers in core European markets, Zur Rose generated revenue of CHF 1,752 million (including external revenue) in 2020.
With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It also excels in continuous development of digital healthcare services and as a platform technology provider. In addition, Zur Rose is actively driving forward its positioning as a comprehensive healthcare service provider, with focus on building up its European healthcare ecosystem networking qualified providers of products, services and digital solutions. Zur Rose's contribution will be to bring these offerings to customers and patients, pursuing its vision of creating a world where people can manage their own health in one click.
The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information, please visit zurrosegroup.com.
^[1] This consists of the consolidated revenue of the Zur Rose Group plus the mail-order revenue of pharmacies supplied by the Zur Rose Group, less the consolidated revenue for their supply.
^[2] Customers supplied by the Zur Rose Group, either directly or through its partners.
-----------------------------------------------------------------------------------------------------------------------
End of ad hoc announcement
(MORE TO FOLLOW) Dow Jones Newswires
August 18, 2021 01:00 ET (05:00 GMT)
